Mode
Text Size
Log in / Sign up
Phase 2 N=424 Randomized Quadruple-blind Treatment

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

Anxiety Disorders

Enrolled (actual)
424
Serious AEs
Results posted
May 2011
Primary outcome: Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.9; -11.1; -11.5; -10.9 Units on scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
AZD7325 (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
AstraZeneca
Primary completion
May 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score
-10.9; -11.1; -11.5; -10.9
SECONDARY
Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score
-4.5; -4.2; -5.2; -4.6
SECONDARY
Change in Psychic Anxiety Symptoms as Measured by HAM-A Psychic Anxiety Factor Score
-5.9; -5.8; -6.5; -5.8
SECONDARY
Change in Somatic Symptoms as Measured by HAM-A Somatic Factor Score
-5.0; -5.3; -5.1; -5.2
SECONDARY
Change in Sheehan Disability Scale (SDS) Global Total Score
-4.7; -5.7; -6.8; -6.8

Summary

The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.

Eligibility Criteria

Inclusion Criteria

  • Signed informed consent before any study-related procedures start.
  • The patient is previously diagnosed with Generalized Anxiety Disorder.
  • The patient has a HADS-A (anxiety) score ≥10 at both screening and randomization.

Exclusion Criteria

  • Patient has a lifetime history of schizophrenia or other psychotic disorders
  • Patient has a history of seizures or seizure disorder.
  • Patient is pregnant or breast feeding.
  • Patient has received electroconvulsive treatment (ECT) in the past.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00808249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search